Basis: Latest reported fiscal quarter. Source: stored company filings and market data; unavailable inputs remain N/A.
The return on equity (ROE) is N/A as of the fiscal period ended Monday, March 31, 2025.
Trailing-twelve-month return on equity at each fiscal quarter end; no daily interpolation. Q1 FY2025 (2025-03-31): -179.50%.
RETURN ON EQUITY (ROE)
N/A
RETURN ON EQUITY (ROE) AVG TTM
-134.55%
RETURN ON EQUITY (ROE) AVG 3Y
-83.78%
RETURN ON EQUITY (ROE) AVG 5Y
-62.32%
RETURN ON EQUITY (ROE) AVG 10Y
N/A
RETURN ON EQUITY (ROE) AVG 15Y
N/A
RETURN ON EQUITY (ROE) AVG 20Y
N/A
CURRENT VS TTM AVG
N/A
CURRENT VS 3Y AVG
N/A
CURRENT VS 5Y AVG
N/A
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
Vor Biopharma Inc.
Market Cap
$992.14M
Return on Equity (ROE)
N/A
TTM Avg
-134.55%
3Y Avg
-83.78%
5Y Avg
-62.32%
Market Cap
$996.65M
Return on Equity (ROE)
-32.27%
TTM Avg
-24.43%
3Y Avg
-32.70%
5Y Avg
-40.03%
Market Cap
$998.69M
Return on Equity (ROE)
-63.62%
TTM Avg
-41.08%
3Y Avg
-23.78%
5Y Avg
-22.76%
Market Cap
$982.46M
Return on Equity (ROE)
-25.78%
TTM Avg
29.18%
3Y Avg
31.59%
5Y Avg
31.59%
Market Cap
$981.66M
Return on Equity (ROE)
36.64%
TTM Avg
876.73%
3Y Avg
395.64%
5Y Avg
252.56%
Market Cap
$1.01B
Return on Equity (ROE)
-52.47%
TTM Avg
-18.98%
3Y Avg
-16.96%
5Y Avg
-116.25%
Market Cap
$978.09M
Return on Equity (ROE)
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$973.93M
Return on Equity (ROE)
2.18%
TTM Avg
-5.89%
3Y Avg
-1.23%
5Y Avg
4.05%
Market Cap
$1.02B
Return on Equity (ROE)
-4.13%
TTM Avg
-0.56%
3Y Avg
-8.16%
5Y Avg
-7.12%
| NAME | MARKET CAP | RETURN ON EQUITY (ROE) | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Vor Biopharma Inc. (VOR) | $992.14M | N/A | -134.55% | -83.78% | -62.32% |
| PROCEPT BioRobotics Corporation (PRCT)vs › | $996.65M | -32.27% | -24.43% | -32.70% | -40.03% |
| Cullinan Therapeutics, Inc. (CGEM)vs › | $998.69M | -63.62% | -41.08% | -23.78% | -22.76% |
| LB Pharmaceuticals Inc Common Stock (LBRX)vs › | $982.46M | -25.78% | 29.18% | 31.59% | 31.59% |
| MeiraGTx Holdings plc (MGTX)vs › | $981.66M | 36.64% | 876.73% | 395.64% | 252.56% |
| Immatics N.V. (IMTX)vs › | $1.01B | -52.47% | -18.98% | -16.96% | -116.25% |
| Latigo Biotherapeutics Inc. (LTGO)vs › | $978.09M | N/A | N/A | N/A | N/A |
| Pacira BioSciences, Inc. (PCRX)vs › | $973.93M | 2.18% | -5.89% | -1.23% | 4.05% |
| Castle Biosciences, Inc. (CSTL)vs › | $1.02B | -4.13% | -0.56% | -8.16% | -7.12% |
| Janux Therapeutics, Inc. (JANX)vs › | $1.02B | -11.06% | -9.32% | -13.81% | -2.96% |
ROE
N/A
ROA
130.5%
ROE = Net Income / Total Shareholders' Equity
Return on equity measures how efficiently a company generates profit from shareholders' equity. Higher ROE indicates better capital efficiency.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | RETURN ON EQUITY (ROE) |
|---|---|
| 2025-03-31 | -179.50% |
| 2024-12-31 | -120.95% |
| 2024-09-30 | -154.15% |
| 2024-06-30 | -120.41% |
| 2024-03-31 | -97.72% |
| 2023-12-31 | -78.20% |
| 2023-09-30 | -66.09% |
| 2023-06-30 | -51.90% |
| 2023-03-31 | -42.48% |
| 2022-12-31 | -36.75% |
| 2022-09-30 | -54.45% |
| 2022-06-30 | -46.41% |
| 2022-03-31 | -40.07% |
| 2021-12-31 | -31.86% |
| 2021-09-30 | -28.46% |
| 2021-06-30 | -23.81% |
| 2021-03-31 | -18.42% |
| 2020-12-31 | -89.78% |
| 2020-09-30 | -49.95% |
| 2020-06-30 | -32.19% |
| 2019-12-31 | -158.46% |
